Takeda Pharmaceutical Company Limited (TAK) – Will global expansion strategy work?

in Company Report, Healthcare & Life Sciences, Pharma & Biotech on February 4, 2022

Takeda’s acquisition of Shire was one of the largest foreign acquisition by a Japanese pharmaceutical company with a value of ¥62bn. This deal has given the organization important global scale including significant expansion in the United States and boosted its long term growth strategy by adding a large portfolio of global brands and increasing the company’s diverse R&D pipeline.

Highlights 

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages : 39

Release Information

  • Released
    :

    February 4, 2022

  • Last Updated
    :

    February 7, 2022